clopidogrel and ibuprofen

Clopidogrel is a prodrug that requires activation by the hepatic enzyme CYP2C19. Ibuprofen is a non-selective COX inhibitor, and the main interaction with clopidogrel is pharmacodynamic, through additive risk of gastrointestinal bleeding: clopidogrel acts via irreversible inhibition of the platelet P2Y12 receptor, and ibuprofen via inhibition of COX-1, which decreases thromboxane A2 and impairs platelet aggregation. The combination therefore results in an additive effect on bleeding risk, particularly in the gastrointestinal tract.

Co-administration of clopidogrel and ibuprofen increases the risk of serious gastrointestinal bleeding, which may be life-threatening. The potential reduction in clopidogrel's antiplatelet activity due to CYP2C19 inhibition could also predispose patients to thrombotic events, such as stent thrombosis or myocardial infarction, although this effect is less clearly established. Patients with a history of peptic ulcer disease, advanced age, or concurrent use of anticoagulants are at particularly high risk.

Avoid the combination if possible. Consider alternative analgesics such as paracetamol or a selective COX-2 inhibitor, depending on the clinical context. If an NSAID is necessary, use the lowest effective dose for the shortest duration, and consider gastroprotection with a proton pump inhibitor (e.g., omeprazole or pantoprazole). Monitor patients for signs of gastrointestinal bleeding (e.g., melaena, haematemesis) and for reduced antiplatelet efficacy. Advise patients to report any unusual bleeding or bruising. Note that the interaction may be less pronounced with ibuprofen doses taken intermittently or after clopidogrel administration, but the safest approach is to avoid concurrent use.

The interaction is based on pharmacokinetic studies showing that ibuprofen inhibits CYP2C19, and pharmacodynamic studies demonstrating increased bleeding risk. Observational data suggest an increased risk of gastrointestinal haemorrhage with combined use. However, the clinical impact on clopidogrel efficacy is inconsistent across studies. The interaction is generally considered well established for the bleeding risk, but the effect on platelet inhibition is debated. No formal randomised controlled trials have specifically evaluated this combination.